MINI FUTURE LONG - ASTRAZENECA | Market Closed - Euronext Paris 17:30:02 03/05/2024 BST | ||
| 5.655 EUR | -2.16% |
|
| 1 month | +40.42% | ||
| 3 months | +48.94% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/05/24 | 5.645 | -2.34% | 329 |
| 02/05/24 | 5.78 | +0.87% | 76 |
| 30/04/24 | 5.73 | 0.00% | 80 |
| 29/04/24 | 5.73 | +1.51% | 74 |
| 26/04/24 | 5.645 | -0.79% | 93 |
Real-time Euronext Paris
Last update May 03, 2024 at 05:30 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
BNP Paribas
|
| 5XJEB | |
| ISIN | NLBNPNL1L647 |
| Date issued | 05/01/2022 |
| Strike | 7,194 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.15 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.145 € |
|---|---|
| Lowest since issue | 1.74 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
151.2
USD
Average target price
164.5
USD
Spread / Average Target
+8.76%
- Stock Market
- Certificates
- 5XJEB Certificat
